Trial Profile
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2022
Price :
$35
*
At a glance
- Drugs Irsenontrine (Primary)
- Indications Dementia; Lewy body disease
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 23 Oct 2020 Status changed from active, no longer recruiting to completed.
- 11 Jul 2020 This trial has been completed in United Kingdom. Global end date of the trial is 20 Apr 2020.
- 28 May 2020 As per European Clinical Trials Database record this trial has been completed in germany global end of the trial is 2020-04-20